Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23973/Hoffmann-La_Roche_logo.svg.png
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
  • Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7%
Antibodies Market Surge: Anticipated 3X Growth by 2032
Antibodies Market Surge: Anticipated 3X Growth by 2032
  Key trends and prospects in terms of product type, application, and end user for the next ten years are provided by Fact.MR in their most recent Antobodies Market research. The study also focuses
Expanding Horizons: Transfection Technologies Market's 7.5% CAGR Forecast
Expanding Horizons: Transfection Technologies Market's 7.5% CAGR Forecast
  According to a recent industry report by market research and competitive intelligence source Fact.MR, the global Transfection Technologies Market is expected to reach US$ 2.27 billion by the end